-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: August 2011
How to Stand Out From the Crowd; Promoting Oklahoma Bioscience
BIO’s annual International Convention has emerged as a must-attend event for countries, states and regions that are hungry for industry investment. The convention gives them the ideal platform to publicize and promote what they have to offer to industry leaders in terms of economic development opportunities. International and domestic public officials take the time to attend because they recognize the enormous potential of the industry. This year’s event drew more than 100 public officials and Read More >
Stopping ALS: An interview with Dr. Perrin from ALS TDI
What is ALS? How widespread is the disease? Are there any treatments for ALS? Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease and outside the US as Motor Neuron Disease (MND) or Charcot’s Disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons) and affects muscle function. Dr. Steven Perrin is the CEO, CSO and Vice Chairman of the ALS Therapy Read More >
State Deficits to Shrink & Taxes Drop – Good News for Biotech
Forecasters at the National Conference of State Legislatures’ 2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years, along with business-friendly tax-cuts. The projections are based on a survey of budget officials in all 50 states last month, said Corina Eckl, director of state services for NCSL. Eckl also noted an emerging trend in which state governors and legislatures are allowing for the expiration of temporary business taxes. Notably, the Michigan Business Read More >
Fall Preview: Business Development Events
Now that the Business Forum and International Convention are behind us, our Business Development department has been gearing up for a very busy Fall schedule. The Line-Up For our first Fall event, BIO returns to India for its 2nd annual BIO India International Partnering Conference September 21st and 22nd. Last year’s conference attracted more than 400 attendees representing 220 companies, from 17 countries around the world, – who scheduled over 750 meetings. We’ve had Read More >
Tech Transfer Summit North America
The National Institutes of Health, BIO, and others are sponsoring the Tech Transfer Summit North America at NIH on 3-4 October 2011. Programming includes Translational Medicine & Funding Innovation, Successful Implementation of Biotech Innovation Strategies Worldwide, and Building Better Academia-Industry Collaborations: How will Big Pharma fill its early-stage Pipeline in 5 years’ time, among other topics. BIO’s President and CEO James C. Greenwood will give one keynote speach on the ”Barriers to Innovation in biotechnology, and Read More >
